David Borg
Overview
Explore the profile of David Borg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palmer D, Jackson R, Springfeld C, Ghaneh P, Rawcliffe C, Halloran C, et al.
J Clin Oncol
. 2024 Dec;
:JCO2401118.
PMID: 39637340
Purpose: The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survival...
2.
Buhmann R, Sayers M, OBrien J, Borg D
PLoS One
. 2024 Nov;
19(11):e0310127.
PMID: 39527599
Purpose: Understanding important features for performance in non-disabled bench press and Paralympic powerlifting may inform talent identification and transfer models. The aim of this scoping review was to describe features...
3.
White N, Parsons R, Borg D, Collins G, Barnett A
J Clin Epidemiol
. 2024 Jun;
173:111433.
PMID: 38897482
Objectives: To describe the characteristics and publication outcomes of clinical prediction model studies registered on clinicaltrials.gov since 2000. Study Design And Setting: Observational studies registered on clinicaltrials.gov between January 1,...
4.
Papadakos K, Gorji-Bahri G, Gialeli C, Hedner C, Hagerling C, Svensson M, et al.
Cancer Immunol Immunother
. 2024 Apr;
73(5):93.
PMID: 38563861
Background: Cartilage oligomeric matrix protein (COMP) is a novel regulator of the tumor microenvironment. Studies in colon cancer and pancreatobiliary adenocarcinoma have revealed COMP expression to be associated with decreased...
5.
Tsekrekos A, Borg D, Johansson V, Nilsson M, Klevebro F, Lundell L, et al.
Ann Surg Oncol
. 2023 Jul;
30(12):7251-7252.
PMID: 37525004
No abstract available.
6.
Tsekrekos A, Borg D, Johansson V, Nilsson M, Klevebro F, Lundell L, et al.
Ann Surg Oncol
. 2023 Jul;
30(12):7196-7205.
PMID: 37505355
Background: Omission of prescheduled chemotherapy following surgery for gastric cancer is a frequent clinical problem. This study examined whether laparoscopic gastrectomy (LG) had a positive impact on compliance with adjuvant...
7.
Borg D, Chircop K, Aquilina D
J Surg Case Rep
. 2023 May;
2023(5):rjad230.
PMID: 37153830
Necrotizing fasciitis is a rare infection that rapidly progresses through fascial planes. Due to the latter, diagnosis in a timely manner is imperative to ultimately decrease morbidity and mortality. Such...
8.
Mezheyeuski A, Backman M, Mattsson J, Martin-Bernabe A, Larsson C, Hrynchyk I, et al.
EBioMedicine
. 2023 Feb;
88:104452.
PMID: 36724681
Background: Cancer immunity is based on the interaction of a multitude of cells in the spatial context of the tumour tissue. Clinically relevant immune signatures are therefore anticipated to fundamentally...
9.
Svensson M, Svensson M, Nodin B, Borg D, Hedner C, Hjalmarsson C, et al.
J Innate Immun
. 2022 May;
14(6):615-628.
PMID: 35504250
Tumor-associated macrophages (TAMs) have emerged as key players in tumor immunology but demonstrate a continuum of functional states being either tumor suppressive or promoting. Moreover, chemotherapeutic agents have been shown...
10.
Cuschieri S, Borg D, Agius S, Scherb H, Grech V
J Egypt Public Health Assoc
. 2022 Feb;
97(1):7.
PMID: 35133544
Background: COVID-19 has severely impacted global healthcare services. Malta has only one acute state hospital, Mater Dei Hospital (MDH), and at the time of writing is the most vaccinated country...